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ANGIOGENESIS INHIBITION HAS THE POTENTIAL TO REDUCE PAIN IN THE
RAT MENISCAL INJURY MODEL OF OSTEOARTHRITIS
S. Ashraf, P.I. Mapp, D.A. Walsh
Arthritis Res. UK Pain Ctr., Academic Rheumatology, Univ. of Nottingham,
Nottingham, United Kingdom
Purpose: The rat meniscal injury (MNX) model of osteoarthritis (OA)
resembles changes observed in human tibiofemoral OA such as cartilage
damage,osteophyte formation and angiogenesis,both in the synovium and
at the osteochondral junction.With its mild to moderate severity and a time
course of 5 weeks it provides a suitable disease model to explore factors
that may either exacerbate or relieve OA.The angiogenesis inhibitor PPI-
2458 is an irreversible inhibitor of the enzyme methionine aminopeptidase
(MetAP)-2.It exerts its anti-angiogenic potential by arresting endothelial
cells in the G1 phase of the cell cycle thereby inhibiting their prolif-
eration.We set out to determine whether angiogenesis inhibition using
PPI-2458 reduces pain and osteoarthritic structural changes in the MNX
model of OA.
Methods: OA pathology was induced by transecting the meniscus in male
Lewis rats (n = 8 per group,weight = 300g) on day 0.Treatment with
PPI-2458 (5mg/kg,orally,every other day) or vehicle control was given
from day 11 to 34.Naïve animals were used as the baseline controls.On
day 35,synovia were harvested and snap frozen.Knee joints were ﬁxed in
neutral buffered formalin or Zamboni’s ﬁxative overnight and decalciﬁed
prior to being cut in coronal sections.Joints were then wax embedded
or frozen in OCT.Tissue sections were cut and stained with haematoxylin
and eosin to assess tissue architecture.Sensory nerves were immunolo-
calised using antibody to the neuropeptide calcitonin gene-related peptide
(CGRP).CD31 positive cells and PCNA immunoreactive CD31 positive cells
were detected to identify endothelial cells and proliferating endothelial
cells respectively in the synovia as two separate measures of the extent of
angiogenesis.Macrophage inﬁltration was identiﬁed by immunoreactivity
for the monoclonal antibody clone ED1.Computer-assisted image analysis
was used to quantify proliferating endothelial cell index and macrophage
fractional area.Pain behaviour [Incapacitance:difference in weight bearing
(g) between the hind paws (right-left)] and joint swelling (knee diameter)
were measured from before surgery until day 35.
Results: Meniscal injury increased pain behaviour in the operated an-
imals compared to naïve controls 12 days after surgery and this dif-
ference was maintained until day 35.Increased joint swelling,cartilage
damage,osteophytes and osteochondral angiogenesis were observed in
the MNX operated animals 35 days after surgery with increased syn-
ovial inﬂammation and angiogenesis compared to naïve controls.Sensory
nerves were located in the osteophytes,synovium and in the subchondral
bone,adjacent to blood vessels.Angiogenesis inhibitor PPI-2458 reduced
weight-bearing assymetry in the MNX model by day 19 compared to vehi-
cle treated animals [25g (95% CI,19 to 31), 46g (95% CI,37 to 55),P<0.01]
and maintained this reduction to day 35 [24g (95% CI,19 to 29), 47g
(95% CI,37 to 57),P<0.001].Pain behaviour however was not completely
abolished to naïve levels.Joint swelling was reduced with PPI-2458 to naïve
levels in the MNX model 14 days after surgery [0.2mm (95% CI,0.01 to 0.2),
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0.1mm (95% CI,0.02 to 0.1),P>0.05] and this reduction was maintained to
day 35,whereas at this point vehicle treated animals still had increased
joint swelling compared to PPI-2458 treated animals [0.4mm (95% CI,0.2 to
0.5),0.05mm (95% CI,-0.01 to 0.1),P<0.01].Synovial macrophage inﬁltration
was similarily reduced to naïve levels in PPI-2458 treated animals.PPI-2458
also reduced synovial angiogenesis at day 35 compared with vehicle treated
animals [1%(95% CI,0.8 to 1.2), 3%(95% CI,1 to 5),P<0.01],to levels similar to
naïve animals [0.6%(95% CI,0.4 to 0.9),P>0.05].
Conclusions: The angiogenesis inhibitor,PPI-2458 inhibited synovial angio-
genesis as well as pain behaviour in the meniscal injury (MNX) model of
OA.Angiogenesis may contribute to pain in OA by enhancing inﬂammation
and nerve growth.
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SYNOVIUM ANGIOGENESIS IN OSTEARTHRITIS: A NEW THERAPY TARGET
FOR CHONDROITIN SULFATE
M. Mathy-Hartert1, C. Lambert1, J.-E. Dubuc2, E. Montell3, J. Vergés3,
Y. Henrotin1
1Bone and Cartilage Res. Unit, Univ. of Liège, Liège, Belgium; 2Orthopaedic
Dept., Cliniques Univ.ires St Luc, Brussels, Belgium; 3Clinical Res. Unit,
Scientiﬁc Med. Dept., Bioibérica S.A., Barcelona, Spain
Purpose: Osteoarthritis (OA) is an important cause of pain and disability
in the ageing population. Angiogenesis and inﬂammation are closely inte-
grated process in OA and may contribute to its pathogenesis, as well as,
affect disease progression and pain. Chondroitin sulfate (CS) is a symp-
tomatic slow acting drug for OA and there is strong evidence suggesting
that CS may also be a structure disease modifying osteoarthritis drug. The
mechanisms underlying these effects remain poorly understood. This work
aimed to demonstrate the relation between inﬂammation and angiogenesis
of synovium and to study the effect of CS on synovium angiogenesis.
Methods: Synovial ﬁbroblast cells (SC) were isolated from OA synovial
specimen obtained from patients undergoing arthroscopy. At the surgery
time, the synovial membrane was dissected and primary SC cells coming
from either inﬂammatory (SCI) or non inﬂammatory (SCNI) area were
cultured separately for 7 days. Pro-angiogenic Vascular Endothelial Growth
Factor (VEGF) and anti-angiogenic thrombospondine (TSP)-1 were then
evaluated in the culture supernatant by speciﬁc sandwich enzyme-linked
immunoabsorbent assay (ELISA). To investigate the effects of Interleukin
(IL)-1beta and CS on pro- and anti- angiogenic factors expression, OA SC
were collected at passage 4. OA SC were then cultured for 5 or 24 h in the
absence or in the presence of IL-1beta (1 ng/ml) and with or without CS (10,
50, 200 μg/ml). Pro-angiogenic factors (VEGF, basic Fibroblast Growth Fac-
tor (bFGF), Nerve Growth Factor (NGF), Matrix Metalloproteinase (MMP)-2,
angiopoietin (ang)-1) and anti-angiogenic factors (TSP-1 and -2, Vascu-
lar Endothelial Growth Inhibitor (VEGI), ang-2 and Platelet Factor (PF)-4
gene expression was determined by real time RT-PCR. Nonparametric
Mann-Whitney test was used to analyze statistical difference.
Results: SCI cells produced more VEGF but less TSP-1 than SCNI cells.
IL-1beta, a pro-inﬂammatory cytokine, induced an imbalance between pro-
and anti-angiogenic factors. IL-1β signiﬁcantly stimulated mRNA expression
of pro-angiogenic factors and drastically inhibited anti-angiogenic factors.
In the basal or IL-1beta treated conditions, CS did not affect the expression
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of pro-angiogenic factors by SC. In IL-1beta treated SC, CS increased the
mRNA expression of the anti-angiogenic factors TSP-1 and VEGI (p < 0.01).
TSP-2 was not affected by CS. The mRNA of anti-angiogenic factors Ang-2
and PF-4 were not detected in our culture conditions.
Conclusions: Synovium inﬂammation is associated with an imbalance
between pro- and anti-angiogenic factors production. IL-1beta is a key
inﬂammatory mediator capable of inducing this pro-angiogenic imbalance.
CS trends to normalize the IL-1beta-induced angiogenic response in OA SC.
This could constitute a new mechanism of action of this drug, modulating
the molecular mechanisms underlying the synovium angiogenesis in OA.
These results also contribute to understand the molecular mechanism of
angiogenesis in OA, leading, in the future, to the development of new
promising therapeutic agents.
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EXPLORATION OF POSSIBLE CATABOLIC FACTORS FOR CARTILAGE
MATRIX IN OSTEOARTHRITIC SYNOVIAL FLUID
N. Fukui1 , Y. Ikeda1, N. Tanaka1, M. Wake1, M. Ohmori1, T. Yamaguchi1,
H. Furukawa1, S. Touma1, Y. Miyamoto2, T. Tashiro3, Y. Katsuragawa4
1Clinical Resarch Ctr., Natl. Hosp. Organization Sagamihara Hosp., Sagamihara,
Kanagawa Pref, Japan; 2Tokyo Metropolitan Geriatric Hosp., Itabashi, Tokyo,
Japan; 3JR Tokyo Gen. Hosp., Shinjyuku, Tokyo, Japan; 4Natl. Ctr. for Global
Hlth.and Med., Shinjyuku, Tokyo, Japan
Purpose: The exact mechanism for cartilage degeneration in osteoarthritis
(OA) is not yet fully known. Although chondrocytes are considered to be
most responsible, synovium could also play a certain role in the loss of car-
tilage. If synovium is indeed involved in cartilage degeneration, a catabolic
factor(s) released from synovium may be found within the synovial ﬂuid. In
this study, we attempted to ﬁnd a possible catabolic factor(s) for cartilage
matrix in synovial ﬂuid from knee OA patients.
Methods: Synovial ﬂuid analysis. The institutional review boards approved
the study project. Synovial ﬂuid was collected from OA knees in the
early stages of the disease (K/L grade I-III) (Early OA knees; n = 53),
and those in the late stage (K/L grade IV) (Advanced OA knees; n = 32).
Concentrations of type II collagen neo-epitope (CIINE) and aggrecan core
protein (ACP), keratin sulfate (KS), and sulfated glucosaminoglycan (sGAG)
were determined respectively to estimate the rate of matrix degeneration.
To ﬁnd possible catabolic factors for cartilage matrix, concentrations of 57
factors that could induce matrix degradation, such as MMPs, cytokines and
chemokines, were determined in those samples by Luminex and ELISA.
Correlation of concentration was investigated between those factors and
the above four cartilage degenerative products.
Determination of the source of possible catabolic factors. Synovial tissues
were obtained from 18 Advanced OA knees with medial involvement for
gene expression analysis by qPCR. Control synovium and cartilage were
obtained from 8 disease-free knees of age-matched donors. In those knees,
synovium was harvetsted at medial, lateral, and patellofemoral compart-
ment, respectively. Synovial tissues from another 8 OA knees were used
to obtain synovial cells. The cells were isolated by enzymic digestion, and
were separated into CD14+ and CD14- cells by magnetic sorting, and gene
expression was analyzed respectively. Some synovial tissues were used for
immunohistochemistry.
Measurement of collagenolytic activity of OA synovial ﬂuid. Synovial ﬂuid
samples from 8 Early OA knees were incubated respectively with bovine
type II collagen with or without MMP activation by APMA. After incubation
at 37°C for 48 hours, the increase in CIINE concentration was determined
by ELISA.
Results: Among the 57 factors evaluated, the concentrations of MMP-1
and 3 were signiﬁcantly correlated with those of the cartilage degenerative
products in both sample groups (Table 1).
The synovial ﬂuid from OA knees contained considerable amounts of
MMP-1 and MMP-3, and their concentrations were closely correlated.
Consistently, the expression of MMP-1 and MMP-3 was highly enhanced
in OA synovium compared with the control, and their expression levels
were strongly correlated there. Although the tissues were obtained from
medially involved knees, these MMPs were expressed at similar levels
across the three compartments. The expression of those MMPs was more
enhanced in CD14- synoviocytes than in CD14+ cells, which was consistent
with the result of immunohistochemistry.
In the last experiment, the concentration of CIINE increased little when the
synovial ﬂuid was incubated with bovine type II collagen. However, when
the MMPs in the ﬂuid were activated by APMA, the CIINE concentration in-
creased dramatically by the incubation in all 8 samples. This collagenolysis
could be ascribed to MMP-1, as the synovial ﬂuid contained little MMP-8
or 13.
Type II collagen degenerative product:
Table 1A. Correlation between CIINE and MMPs




Table 1B. Correlation between ACP and MMPs
Early OA Advanced OA
MMP-1 p<0.001 NS
MMP-3 p<0.01 p<0.05
Conclusions: In OA joints, ﬁbroblast-like synoviocytes may release MMP-1
and MMP-3 into synovial ﬂuid, which could play a certain role in cartilage
degeneration. MMPs (most likely MMP-1) in synovial ﬂuid can degrade
type II collagen rather eﬃciently when activated, even in the presence of
TIMPs and α2-macroglobulin in the ﬂuid.
088
MITOCHONDRIAL DYSFUNCTION PROMOTES PRO-INFLAMMATORY
RESPONSES IN CULTURED NORMAL HUMAN SYNOVIOCYTES
M.N. Valcárcel-Ares1 , R.R. Riveiro-Naveira1, C. Vaamonde-Garcia1,
F.J. Blanco2, M.J. López-Armada1
1Inﬂammation and Aging Unit - INIBIC - CHUAC, A Coruña, Spain;
2Osteoarticular and Aging Res. Lab. - INIBIC - CHUAC, A Coruña, Spain
Purpose: Inﬂammation hypothesis of aging suggests that molecular in-
ﬂammation could be an underpinning of aging and age-related diseases,
as Rheumatoid Arthritis (RA). Besides, mitochondrial alterations may
contribute to the progression of RA. In this study, we investigated the re-
lationship between mitochondrial dysfunction and the in vitro expression
of cyclooxigenase-2 (COX-2), prostaglandin E2 (PGE2), and interleukin-8
(IL-8) in normal human synoviocytes.
Method: Commonly used inhibitors to induce mitochondrial dysfunction
were employed [Antimycin A (AA) and Oligomycin (OLI), inhibitors of
complexes III and V of mitochondrial respiratory chain (MRC), respectively]
in synoviocytes. IL-1β and TNF-α were used as inﬂammatory mediators. To
identify possible pathways, we used N-acetylcysteine as ROS scavenger; the
natural antioxidant resveratrol; and BAY as an inhibitor of NF-kB activation.
COX-2 protein and mRNA expression and both PGE2 and IL-8 levels were
analyzed by ﬂow cytometry, RT-PCR and ELISA, respectively.
Results: First, we found that exposure of synoviocytes to AA and OLI signif-
icantly increased COX-2 protein expression in a time- and dose-dependent
manner. The maximal response was observed at 6h with 20μg/ml AA and
25μg/ml OLI (3.0±0.3, n=4, p<0.001 and 6.5±1.9, n=9 p<0.001, respec-
tively vs. basal 1) while the positive control, 1ng/ml IL-1β, expression
was 12.6±3.4. Quantiﬁcation of COX-2 mRNA expression at 4h showed
similar results. PGE2 levels were also signiﬁcantly increased when cells
were stimulated for 9h with OLI. Second, we tested if mitochondrial
dysfunction could modulate the response induced by sub-optimal doses
of IL-1β (0.1ng/ml) on COX-2 protein expression and PGE2 production.
We found that pre-treatment of synoviocytes with 10μg/ml OLI for 30
minutes signiﬁcantly increases the IL-1β-induced COX-2 protein expression
(32.5±2.5 OLI+IL-1β vs. 6.5±2.4 IL-1β and 4.5±1.7 OLI, n=3, p<0.001) and
COX-2 mRNA expression. Similar results were obtained when PGE2 produc-
tion was assessed (277.0±67.6 OLI+IL-1β vs. 15.4±2.6 IL-1β and 97.5±45.6
OLI, expressed as pg/50,000cells, n=3 duplicate, p<0.005). Equivalent re-
sults were observed when TNF-α or AA was employed. Besides, we also
explored that OLI together with IL-1β signiﬁcantly potentiates the expres-
sion of the pro-inﬂammatory chemokine IL-8 (2886.6±272.6 OLI+IL-1β vs.
1313.1±201.2 IL-1β and 62.4±15.4 OLI, expressed as pg/50,000cells, n=4,
p<0.001).
Finally, we observed that this inﬂammatory response was counteracted
by the addition of N-acetylcysteine, resveratrol or BAY, demonstrating the
involvement of ROS and NF-kB in this process.
